Lymphocytic Choriomeningitis Virus (LCMV) Infection Treatment & Management

Updated: Sep 11, 2017
  • Author: Philip J McDonald, MD; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print

Medical Care

No antiviral agents have undergone clinical trials for the treatment of lymphocytic choriomeningitis virus (LCMV) infection.

Early diagnosis and supportive care (eg, fluid replacement, NSAID therapy) are essential, particularly in immunocompromised patients. Reduce immunosuppression, when feasible.

No specific drug treatment is indicated in most cases of LCMV infection. Most patients improve spontaneously within 1-3 weeks with no sequelae.

Ribavirin has in vitro activity against LCMV and has been used with success in transplant recipients with severe disease. Intravenous ribavirin is not commercially available. Oral ribavirin is dosed based on ideal body weight and renal function. Patients should be monitored carefully for potential toxicity, including hemolytic anemia, while receiving ribavirin. [20, 14]

Favipiravir (T-705), a selective inhibitor of RNA-dependent RNA polymerase (RdRp), has been shown to inhibit LCMV in vitro. It has also demonstrated promising efficacy at reducing mortality of other arenavirus infections in animal models. Further study is needed to ascertain if favipiravir could be safely used to treat infections with arenaviruses, including LCMV in humans. [21, 22]